Ticker > Company >

Zydus Lifesciences share price

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE BSE: 532321 SECTOR: Pharmaceuticals & Drugs  3.54 L   2.44 K   660

1044.85
+1.35 (0.13%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1054.55

Today's Low

₹ 1042.15

52 Week High

₹ 1135.95

52 Week Low

₹ 797.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

105136.36 Cr.

Enterprise Value

113330.96 Cr.

No. of Shares

100.62 Cr.

P/E

23.58

P/B

4.87

Face Value

₹ 1

Div. Yield

1.05 %

Book Value (TTM)

₹  214.41

CASH

144.1 Cr.

DEBT

8338.7 Cr.

Promoter Holding

74.99 %

EPS (TTM)

₹  44.31

Sales Growth

39.72%

ROE

31.29 %

ROCE

30.86%

Profit Growth

67.8 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Zydus Lifesciences Ltd.

FALCIGO NUCOXIA OCID NUCOXIA MR LINID OXALGIN BURPEX COLIRID PAZUBID OFLIN O NUCOXIA SP TOLFREE IKMAG METSCORE XL OXALGIN MR METSCORE AM ARZEP ZYAQUA LATINA RT BRIOPT MOXTIF ILAZ ZYONATE ZYOPTA MOXTIF K AMNAC ZYVISC CYCLODROP Remdac TwinRab VaxiFlu 4 Aten DERIPHYLLIN DOXOLIN ORNI O NEUROMET DEZOCORT

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year39.72%
3 Year24.48%
5 Year18.95%

Profit Growth

1 Year67.8%
3 Year88.81%
5 Year32.52%

ROE%

1 Year31.29%
3 Year22.04%
5 Year17%

ROCE %

1 Year30.86%
3 Year22.42%
5 Year17.27%

Debt/Equity

0.3935

Price to Cash Flow

33.76

Interest Cover Ratio

16.2243

CFO/PAT (5 Yr. Avg.)

0.740987943148543

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 74.99 0.00
Mar 2025 74.99 0.00
Dec 2024 74.98 0.00
Sep 2024 74.98 0.00
Jun 2024 74.98 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 88.8147567739624% for the Past 3 years.
  • The company has shown a good revenue growth of 24.4799622899145% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.0398% over the past 3 years.
  • Company has been maintaining healthy ROCE of 22.4186333333333% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 16.2243.
  • The Company has been maintaining an effective average operating margins of 32.7257976782221% in the last 5 years.
  • Company’s PEG ratio is 0.347769435044287.
  • The company has an efficient Cash Conversion Cycle of 25.2692 days.
  • The company has a high promoter holding of 74.99%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.27310346097333.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 4160.2 2620.6 2515.9 5819.6 2588.3
Total Expenditure 1787.3 1733 1867.4 2046.9 2002.9
Operating Profit 2372.9 887.6 648.5 3772.7 585.4
Other Income 106.6 381.3 77.5 185.4 157.1
Interest 115.4 95.9 97.2 155.4 137.6
Depreciation 130.6 133.7 131.6 128 130
Exceptional Items 0 0 0 0 0
Profit Before Tax 2233.5 1039.3 497.2 3674.7 474.9
Tax 532.7 249.5 26.6 861 90.2
Profit After Tax 1700.8 789.8 470.6 2813.7 384.7
Adjusted EPS (Rs) 16.91 7.85 4.68 27.97 3.82

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 7780 7836.9 8731.6 10818.7 15116.3
Total Expenditure 5472.6 6065.5 6553.2 6838.1 7589.6
Operating Profit 2307.4 1771.4 2178.4 3980.6 7526.7
Other Income 90.6 325.4 824.4 1162.9 930.9
Interest 70.9 134.9 278.2 390.7 489
Depreciation 451.1 478.7 488.6 504.4 523.9
Exceptional Items -187.5 -319.3 -203.8 -8.6 0
Profit Before Tax 1688.5 1163.9 2032.2 4239.8 7444.7
Tax 212.3 306 503 798.3 1669.8
Net Profit 1476.2 857.9 1529.2 3441.5 5774.9
Adjusted EPS (Rs.) 14.42 8.38 15.11 34.21 57.4

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 102.4 102.4 101.2 100.6 100.6
Total Reserves 12642.1 13138.1 13538.2 15615.9 21089.5
Borrowings 609.5 126.4 3771 5555.4 2862.1
Other N/C liabilities 1569 1660.4 1624.3 1832.5 1913.8
Current liabilities 5163.5 4898.1 4051.2 4392 11071.1
Total Liabilities 20086.5 19925.4 23085.9 27496.4 37037.1
Assets
Net Block 4112 4335.9 4184.1 4369.4 4202.1
Capital WIP 570.5 384 739.3 626.7 1188.5
Intangible WIP 0 0 0 7.2 0
Investments 6470.6 4897.5 4677.7 7283 7255
Loans & Advances 2398.1 2424.6 4626 5415.3 5848.2
Other N/C Assets 161.1 175.8 439.5 32.9 8.9
Current Assets 6374.2 7707.6 8419.3 9761.9 18534.4
Total Assets 20086.5 19925.4 23085.9 27496.4 37037.1
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1688.5 1163.9 2032.2 4239.8 7444.7
Adjustment 611.4 761.1 475.1 -149 325.1
Changes in Assets & Liabilities 191.1 -382.8 -1035.9 -1192.8 -3307.7
Tax Paid -263.8 -270 -393.2 -897.7 -1348.1
Operating Cash Flow 2227.2 1272.2 1078.2 2000.3 3114
Investing Cash Flow -2713.8 586.2 -1959.3 -1831.8 -4503.6
Financing Cash Flow 255.3 -1709.8 827 -300.8 1384.5
Net Cash Flow -231.3 148.6 -54.1 -132.3 -5.1

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 74.98 74.98 74.98 74.99 74.99
arati rajiv mehta - - - 0.01 0.01
zydus family trust (panka... 74.96 74.96 74.96 74.96 74.96
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 25.02 25.02 25.02 25.01 25.01
icici prudential bluechip... - 1.40 1.81 1.76 1.74
investor education and pr... - - 0.17 - 0.17
kotak flexicap fund 1.71 1.50 1.37 1.40 1.23
life insurance corporatio... - - - 3.85 4.62
llp 0.03 0.03 0.03 0.03 0.03
parag parikh flexi cap fu... - - - 1.34 1.49
investor education and pr... 0.17 0.17 - 0.17 -
llife insurance corporati... 3.89 3.09 3.53 - -
icici prudential focus eq... 1.26 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Geojit
Research Geojit
Research HDFC Securities
Research Sharekhan
Research Motilal Oswal
Research Geojit BNP Paribas
Research ICICI Securities Limited
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q4FY19
Concall Q3FY24
Concall Q3FY22
Concall Q3FY22
Concall Q2FY25
Concall Q2FY24
Concall Q2FY23
Concall Q2FY22
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY19
Presentation Q3FY24
Presentation Q3FY22
Presentation Q3FY21
Presentation Q2FY23
Presentation Q2FY22
Presentation Q1FY25
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21
Presentation Q3FY20

Company News

Zydus Lifesciences Stock Price Analysis and Quick Research Report. Is Zydus Lifesciences an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Zydus Lifesciences. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Zydus Lifesciences has a PE ratio of 23.57724127659 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Zydus Lifesciences has ROA of 17.8974% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Zydus Lifesciences has a Current ratio of 1.6741.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Zydus Lifesciences has a ROE of 31.2947%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Zydus Lifesciences has a Debt to Equity ratio of 0.3935 which means that the company has low proportion of debt in its capital.

  • Sales growth: Zydus Lifesciences has reported revenue growth of 39.7238% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Zydus Lifesciences for the current financial year is 49.7919464419203%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Zydus Lifesciences is Rs 11 and the yield is 1.0528%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Zydus Lifesciences is Rs 44.3118. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Zydus Lifesciences in Ticker for free. Also, one can get the intrinsic value of Zydus Lifesciences by using Valuation Calculators, which are available with a Finology ONE subscription. 

Zydus Lifesciences FAQs

Q1. What is Zydus Lifesciences share price today?
Ans: The current share price of Zydus Lifesciences is Rs 1044.75.

Q2. What is the market capitalisation of Zydus Lifesciences?
Ans: Zydus Lifesciences has a market capitalisation of Rs 105126.29610525 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Zydus Lifesciences?
Ans: The PE ratio of Zydus Lifesciences is 23.57724127659 and the P/B ratio of Zydus Lifesciences is 4.87263748789711, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Zydus Lifesciences share?
Ans: The 52-week high share price of Zydus Lifesciences is Rs 1133, and the 52-week low share price of Zydus Lifesciences is Rs 795.

Q5. Does Zydus Lifesciences pay dividends?
Ans: Currently, Zydus Lifesciences pays dividends. Dividend yield of Zydus Lifesciences is around 1.0528%.

Q6. What are the face value and book value of Zydus Lifesciences shares?
Ans: The face value of Zydus Lifesciences shares is Rs 1, while the book value per share of Zydus Lifesciences is around Rs 214.4116. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Zydus Lifesciences?
Ans: Zydus Lifesciences has a total debt of Rs 8338.7 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Zydus Lifesciences?
Ans: The ROE of Zydus Lifesciences is 31.2947% and ROCE of Zydus Lifesciences is 30.8591%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Zydus Lifesciences a good buy for the long term?
Ans: The Zydus Lifesciences long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Zydus Lifesciences undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Zydus Lifesciences appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Zydus Lifesciences’s financials?
Ans: You can review Zydus Lifesciences’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Zydus Lifesciences
X